Frost and Sullivan recently published a report stating that FemTech will be a $50 billion market by 2025. Spurred on by rapid innovation in the health space, a positive regulatory environment and the fact that women now control 80% of healthcare decisions in the U.S. household, FemTech is predicted to be the next big disruptor in the global healthcare market. While the benefits of FemTech are widely recognized, the market is still at an early stage.

"It is our investment philosophy to focus on opportunities in high-growth potential segments that are unfulfilled by the traditional venture capital marketplace while being guided by some of the strongest experts in the industry," says Portfolia Co-Founder and CEO Trish Costello. "For the first time ever, women have the majority of the wealth in the U.S., and are beginning to embrace their power as market makers. They are vocal in their intent to make investments that both have an impact and see returns – the FemTech Fund is a natural fit for this growing market."

"Only 1.4% of healthcare investing by professional venture capitalists is put to work to find solutions in the women's health space – or FemTech. 80% of healthcare VC's have never invested in healthcare for women," Masterson comments. "This underserved market enables Portfolia to access the best deals with very reasonable valuations. I'm excited about the quantity and caliber of companies that are coming across my desk."

Portfolia is no stranger to investing in cutting-edge companies in the FemTech space. The venture investment group firm has most recently funded JoyLux, run by the former Clarisonic/Sonicare team, which has an innovative product suite to address bladder control and post-partum vaginal rejuvenation. Madorra, the first non-hormonal treatment to address vaginal dryness, and Sandstone Diagnostics, a fertility tracking company join JoyLux as promising Portfolia investments in the FemTech space.

Faz K. Bashi adds, "I'm thrilled to able to head up a fund focused on improving the health, wellness, and lives of women by bringing emerging women's health solutions to market at a time when there is such market opportunity. Portfolia takes the diversification and management of more traditional venture and layers in more opportunities for education and engagement. I'm thrilled to be part of their mission to build an investment community of 100,000 women venture investors by 2022."

Portfolia is a website operated by Portfolia, Inc. By accessing this site and any pages hereof, you agree to be bound by the Terms of Service and Privacy Policy. Portfoliadoes not make investment recommendations, and no communication through this website or otherwise should be construed as a recommendation for any offer of a security referenced on this website or otherwise. Companies or individuals providing information on this site are solely responsible for their content. All investors in Portfolia Funds must be accredited investors. Investing in private placements requires high tolerance for risk and illiquidity, and investors must be able to afford to lose their entire investment.

Information about any securities offering should not be considered complete and is qualified by the full offering documents corresponding to the financing. The information contained here or in any correspondence or attachment hereto may include forward-looking statements, estimates, projections and/or representations. To the fullest extent permissible by law, neither Portfolia, Inc. nor its funds; nor any of their managers or non-managing members, employees, representatives, or agents makeany representation or warranty, express or implied, as to the accuracy, completeness or definitiveness of this information, and nothing contained herein shall be relied upon as a representation as to past or future performance. We are not a registered broker, dealer, investment advisor, investment manager or funding portal. Portfolia Inc. and Portfolia Managing Member do not give investment advice, provide analysis or recommendations.

*IRS Circular 230 Disclosure: To ensure compliance with requirements imposed by the IRS, we inform you that any tax advice contained in this communication (including any attachments) was not intended or written to be used and cannot be used, for the purpose of (i) avoiding any tax penalty or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein.